DK0728144T3 - Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer af metalloproteinaser - Google Patents

Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer af metalloproteinaser

Info

Publication number
DK0728144T3
DK0728144T3 DK95900237T DK95900237T DK0728144T3 DK 0728144 T3 DK0728144 T3 DK 0728144T3 DK 95900237 T DK95900237 T DK 95900237T DK 95900237 T DK95900237 T DK 95900237T DK 0728144 T3 DK0728144 T3 DK 0728144T3
Authority
DK
Denmark
Prior art keywords
inhibitors
metalloproteinases
therapeutic use
peptidyl compounds
matrix metalloproteinase
Prior art date
Application number
DK95900237T
Other languages
English (en)
Inventor
John Montana
Jonathon Dickens
David Alan Owen
Andrew Douglas Baxter
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Application granted granted Critical
Publication of DK0728144T3 publication Critical patent/DK0728144T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK95900237T 1993-11-10 1994-11-10 Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer af metalloproteinaser DK0728144T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939323165A GB9323165D0 (en) 1993-11-10 1993-11-10 Compounds
PCT/GB1994/002471 WO1995013289A1 (en) 1993-11-10 1994-11-10 Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases

Publications (1)

Publication Number Publication Date
DK0728144T3 true DK0728144T3 (da) 2000-07-03

Family

ID=10744943

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95900237T DK0728144T3 (da) 1993-11-10 1994-11-10 Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer af metalloproteinaser

Country Status (22)

Country Link
US (1) US5853623A (da)
EP (1) EP0728144B1 (da)
JP (1) JPH09505041A (da)
KR (1) KR960705843A (da)
CN (1) CN1134705A (da)
AT (1) ATE188969T1 (da)
AU (1) AU679286B2 (da)
BR (1) BR9408025A (da)
CA (1) CA2173470A1 (da)
CZ (1) CZ287780B6 (da)
DE (1) DE69422726T2 (da)
DK (1) DK0728144T3 (da)
ES (1) ES2143611T3 (da)
FI (1) FI961976A0 (da)
GB (1) GB9323165D0 (da)
GR (1) GR3033103T3 (da)
HK (1) HK1015139A1 (da)
HU (1) HU217344B1 (da)
NO (1) NO961888L (da)
PL (1) PL180403B1 (da)
PT (1) PT728144E (da)
WO (1) WO1995013289A1 (da)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09503201A (ja) * 1993-08-23 1997-03-31 イミュネックス・コーポレーション Ｔｎｆ−アルファ分泌の阻害剤
GB9414157D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Medical use
GB9601042D0 (en) * 1996-01-17 1996-03-20 Smithkline Beecham Plc Medical use
CA2201639A1 (en) * 1994-10-05 1996-04-18 John Montana Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
JPH11504934A (ja) * 1995-05-10 1999-05-11 カイロサイエンス・リミテッド 金属プロテアーゼとｔｎｆの放出を抑制するペプチジル化合物およびその治療的使用
US6110896A (en) * 1995-05-10 2000-08-29 Darwin Discovery, Ltd. Peptidyl compounds and their therapeutic use
CA2217850A1 (en) * 1995-05-10 1996-11-14 Chirotech Technology Limited Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use
US5677282A (en) * 1995-06-07 1997-10-14 Proscript, Inc. Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase
GB2318353B (en) * 1995-07-20 1999-10-06 British Biotech Pharm Metalloproteinase inhibitors
GB9514867D0 (en) * 1995-07-20 1995-09-20 British Biotech Pharm Metalloproteinase inhibitors
JP2008024720A (ja) * 1995-07-26 2008-02-07 Mitsubishi Chemicals Corp ペニシラミンアミド誘導体
CN1145637C (zh) * 1995-10-05 2004-04-14 达尔文发现有限公司 作为金属蛋白酶和tnf释放抑制剂的硫取代的肽
AU7139996A (en) * 1995-10-05 1997-04-28 Chiroscience Limited Mercaptoamide derivatives and their therapeutic use
GB9523066D0 (en) * 1995-11-10 1996-01-10 Chiroscience Ltd Compounds and their therapeutic use
BR9611636A (pt) * 1995-11-22 1999-12-28 Darwin Discovery Ltd Compostos de mercaptoalquilpeptidila que apresentam um substituinte imdazol e seu uso como inibidores de metaloproteinases de matriz (mmp) e/ou como fator de necrose de tumores (tnf).
ES2284180T3 (es) 1996-01-23 2007-11-01 SHIONOGI & CO., LTD. Derivados de aminoacidos sulfonados e inhibidores de metaloproteinasas que contienen los mismos.
US6919375B1 (en) 1996-01-23 2005-07-19 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
GB9607249D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9607119D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
AU710079B2 (en) * 1996-04-04 1999-09-16 F. Hoffmann-La Roche Ag Use of derivatives of tetrahydro-beta-carbolines as antimetastatic agents
GB9609702D0 (en) 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
US5852213A (en) * 1996-07-10 1998-12-22 American Cyanamid Company Mercaptoketones and mercaptoalcohols and a process for their preparation
ES2194209T3 (es) * 1996-07-22 2003-11-16 Monsanto Co Inhibidores de metaloproteasa de tiol sulfona.
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
GB9624817D0 (en) * 1996-11-28 1997-01-15 British Biotech Pharm Metalloproteinase inhibitors
JP2001513813A (ja) * 1997-03-03 2001-09-04 ダーウィン・ディスカバリー・リミテッド 副作用の少ない選択的ｍｍｐインヒビター
US6476027B1 (en) 1997-03-04 2002-11-05 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
CN1105114C (zh) 1997-03-04 2003-04-09 孟山都公司 芳族磺酰基α－羟基异羟肟酸化合物
WO1998039315A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
WO1998039326A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
US6034136A (en) 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors
WO1999007679A1 (en) * 1997-08-08 1999-02-18 Chiroscience Limited Peptidyl compounds having mmp and tnf inhibitory activity
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
IL135106A0 (en) 1997-11-14 2001-05-20 Searle & Co Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
AUPP508798A0 (en) * 1998-08-05 1998-08-27 Biotech Australia Pty Limited Method of treating psoriasis
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
JP2002534410A (ja) * 1998-12-31 2002-10-15 アベンティス・ファーマスーティカルズ・インコーポレイテツド アミドマロンアミド類およびマトリックスメタロプロテイナーゼ阻害剤としてのそれらの用途
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
CZ20012849A3 (cs) 1999-02-08 2002-05-15 G. D. Searle & Co. Corporate Patent Dept. Inhibitor metaloproteáz kyselina sulfamátohydroxamová
EP1192128A4 (en) * 1999-06-15 2003-07-02 Merck & Co Inc THIOL DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS
US6869951B1 (en) 1999-07-16 2005-03-22 Pharmacia Corporation Method of changing conformation of a matrix metalloproteinase
US6696456B1 (en) * 1999-10-14 2004-02-24 The Procter & Gamble Company Beta disubstituted metalloprotease inhibitors
AU2001245891A1 (en) 2000-03-21 2001-10-03 The Procter & Gamble Company Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
PL357275A1 (en) * 2000-03-21 2004-07-26 The Procter & Gamble Company Carbocyclic side chain containing metalloprotease inhibitors
EP1265865A2 (en) * 2000-03-21 2002-12-18 The Procter & Gamble Company Difluorobutyric acid derivatives and their use as metalloprotease inhibitors
US6683093B2 (en) 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
FR2823212B1 (fr) * 2001-04-10 2005-12-02 Inst Nat Sante Rech Med Inhibiteurs de la toxine botulique de type b
AR040928A1 (es) 2001-05-11 2005-04-27 Pharmacia Corp Compuestos de acidos sulfona-hidroxamicos aromaticos, composiciones farmaceuticas y su uso en la preparacion de medicamentos utiles como inhibidores de proteasas
MXPA04010555A (es) 2002-04-25 2005-02-17 Pharmacia Corp Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa.
ES2342378T3 (es) * 2002-08-20 2010-07-06 Astellas Pharma Inc. Inhibidor de degradacion de matriz extracelular del cartilago artrodial.
EP1594459B1 (en) 2002-12-30 2010-02-17 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7570250B2 (en) * 2006-05-04 2009-08-04 Yi-Ming Tseng Control device including a ball that stores data
WO2010118435A2 (en) 2009-04-10 2010-10-14 Tufts Medical Center, Inc. Par-1 activation by metalloproteinase-1 (mmp-1)
JP2019525947A (ja) 2016-06-01 2019-09-12 エムスリー・バイオテクノロジー・インコーポレイテッドＭ３ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE60751B1 (en) * 1986-12-24 1994-08-10 Beecham Group Plc Derivatives of n-(2-alkyl-3-mercapto-glutaryl) alpha-amino acids and their use as collagenase inhibitors
ATE106087T1 (de) * 1987-03-17 1994-06-15 Res Corp Technologies Inc Synthetische inhibitoren von säugetier- collagenase.
US5144043A (en) * 1988-06-15 1992-09-01 Centocor Cleavable bifunctional coupling agents
AU5292193A (en) * 1992-10-02 1994-04-26 Merck & Co., Inc. N-(mercaptoacyl)peptidyl derivatives as antidegenerative agents

Also Published As

Publication number Publication date
CN1134705A (zh) 1996-10-30
PL314300A1 (en) 1996-09-02
ATE188969T1 (de) 2000-02-15
GR3033103T3 (en) 2000-08-31
KR960705843A (ko) 1996-11-08
EP0728144A1 (en) 1996-08-28
AU8113394A (en) 1995-05-29
GB9323165D0 (en) 1994-01-05
HU9601244D0 (en) 1996-07-29
US5853623A (en) 1998-12-29
NO961888D0 (no) 1996-05-09
PL180403B1 (pl) 2001-01-31
JPH09505041A (ja) 1997-05-20
HK1015139A1 (en) 1999-10-08
CZ134996A3 (en) 1996-10-16
ES2143611T3 (es) 2000-05-16
DE69422726D1 (de) 2000-02-24
AU679286B2 (en) 1997-06-26
CZ287780B6 (en) 2001-02-14
WO1995013289A1 (en) 1995-05-18
FI961976A (fi) 1996-05-09
BR9408025A (pt) 1996-12-17
HUT73799A (en) 1996-09-30
NO961888L (no) 1996-05-09
CA2173470A1 (en) 1995-05-18
FI961976A0 (fi) 1996-05-09
DE69422726T2 (de) 2000-06-08
HU217344B1 (hu) 2002-02-28
EP0728144B1 (en) 2000-01-19
PT728144E (pt) 2000-07-31

Similar Documents

Publication Publication Date Title
DK0728144T3 (da) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer af metalloproteinaser
NO971537L (no) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer for metalloproteaser
NO20000784L (no) Nye aggrecanaseinhibitorer og matriksmetalloproteinaser for behandling av artritt
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
NO963499L (no) Hydroksaminsyre- og karboksylsyrederivater, fremgangsmåte for deres fremstilling og anvendelse derav
NO982185L (no) Nye makrosykliske forbindelser som metalloproteinaseinhibitorer
ATE266675T1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
DK1119362T3 (da) Anvendelse af tetracyclinderivater til forögelse af interleukin-10-produktion
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
EA200001223A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
PT705100E (pt) Guanidinas substituidas terapeuticas
BR9713178A (pt) Inbidores espirocìclicos da metaloprotease.
NO982290D0 (no) Merkaptoalkylpeptidyl-forbindelser som har en imidazolsubstituent og deres anvendelse som inhibitorer av matriks-metalloproteinaser (MMP) og/eller tumor nekrosefaktor (TNF)
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE69837322D1 (de) Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
NO20030155D0 (no) Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav
ATE250030T1 (de) Peptidverbindungen mit mmp- und tnf-hemmender wirkung
BR9906719A (pt) "n-óxidos de compostos heterocìclicos com atividade inibidora de tnf e de pde-iv"
NO972906D0 (no) 4,4-(Disubstituerte)cykloheksan-1-ol-monomerer og beslektede forbindelser
PT1169054E (pt) Produtos e metodos para tratar doencas relacionadas com ptp lar